Aktienanalyse zu Neurocrine Biosciences, Inc (NBIX)NBIXNeurocrine Biosciences, Inc

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator॥ / (AMPA PAM) and others. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Neurocrine Biosciences Inc is a good buy right now due to its strong financial performance, with a gross margin of 95.87% in Q2 2026 and a forward P/E ratio of 14.1243, indicating attractive valuation. Additionally, analyst targets suggest significant upside potential, with Guggenheim setting a price target of $207, implying about 45% upside from the current price of $142.7. However, the main risk is the safety concerns surrounding the VYKAT XR acquisition, which has led to market skepticism and could impact future revenues.

13 analysts cover NBIX: 13 rate it Buy, 0 Hold and 0 Sell. The average price target is 179.68.